Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.3389/FPHYS.2020.00619 | ||||
| Año | 2020 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Molar Hypomineralisation (MH) is gaining cross-sector attention as a global health problem, making deeper enquiry into its prevention a research priority. However, causation and pathogenesis of MH remain unclear despite 100 years of investigation into "chalky" dental enamel. Contradicting aetiological dogma involving disrupted enamel-forming cells (ameloblasts), our earlier biochemical analysis of chalky enamel opacities implicated extracellular serum albumin in enamel hypomineralisation. This study sought evidence that the albumin found in chalky enamel reflected causal events during enamel development rather than later association with pre-existing enamel porosity. Hypothesising that blood-derived albumin infiltrates immature enamel and directly blocks its hardening, we developed a "molecular timestamping" method that quantifies the adult and fetal isoforms of serum albumin ratiometrically. Applying this novel approach to 6-year molars, both isoforms of albumin were detectable in 6 of 8 chalky opacities examined (corresponding to 4 of 5 cases), indicating developmental acquisition during early infancy. Addressing protein survival,in vitroanalysis showed that, like adult albumin, the fetal isoform (alpha-fetoprotein) bound hydroxyapatite avidly and was resistant to kallikrein-4, the pivotal protease involved in enamel hardening. These results shift primary attention from ameloblast injury and indicate instead that an extracellular mechanism involving localised exposure of immature enamel to serum albumin constitutes the crux of MH pathogenesis. Together, our pathomechanistic findings plus the biomarker approach for onset timing open a new direction for aetiological investigations into the medical prevention of MH.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Williams, Rebecca | Mujer |
Univ Melbourne - Australia
University of Melbourne - Australia Melbourne Dental School - Australia |
| 2 | PEREZ-VALDES, VIDAL ANTONIO | Hombre |
Univ Melbourne - Australia
Universidad de Talca - Chile University of Melbourne - Australia |
| 3 | Mangum, Jonathan E. | Hombre |
Univ Melbourne - Australia
University of Melbourne - Australia |
| 4 | Hubbard, Michael J. | Hombre |
Univ Melbourne - Australia
University of Melbourne - Australia Melbourne Dental School - Australia Faculty of Medicine, Dentistry and Health Sciences - Australia |
| Fuente |
|---|
| University of Talca |
| Becas Chile |
| University of Melbourne |
| National Health and Medical Research Council |
| Department of Paediatrics at the University of Melbourne |
| Department of Pharmacology & Therapeutics |
| Melbourne Research Unit for Facial Disorders |
| NHMRC, Australia |
| Faculty of Medicine, Dentistry and Health Science (MH) at the University of Melbourne |
| Department of Pharmacology & Therapeutics at the University of Melbourne |
| Melbourne Research Unit for Facial Disorders at the University of Melbourne |
| Department of Paediatrics |
| Faculty of Medicine, Dentistry and Health Science |
| Royal Melbourne Hospital |
| Agradecimiento |
|---|
| This work was supported by the Melbourne Research Unit for Facial Disorders (MH, JM, RW and VP), Department of Pharmacology & Therapeutics (MH, JM, RW, and VP), Department of Paediatrics, and Faculty of Medicine, Dentistry and Health Science (MH) at the University of Melbourne. JM held a Peter Doherty early career fellowship from NHMRC, Australia. VP additionally received Ph.D. scholarship support in Melbourne from Becas Chile and the University of Talca where he now holds a faculty position. |
| We thank Ray Czajko and Maria Bisignano (Clinical Pathology Laboratory, Royal Melbourne Hospital) for undertaking the clinical assays on AFP, Paul Monagle and Vera Ignjatovic (The University of Melbourne) for neonatal serum, and local members of The D3 Group (thed3group.org) for MH specimens and ideas. Thanks also to James Ziogas (Department of Pharmacology & Therapeutics, The University of Melbourne) for numerous contributions throughout this work, and to David Manton (Melbourne Dental School) for co-supervision (RW and VP). Oliver Thomas, Garry Nervo, and Roger Hall are acknowledged for their critique of the manuscript. Funding. This work was supported by the Melbourne Research Unit for Facial Disorders (MH, JM, RW and VP), Department of Pharmacology & Therapeutics (MH, JM, RW, and VP), Department of Paediatrics, and Faculty of Medicine, Dentistry and Health Science (MH) at the University of Melbourne. JM held a Peter Doherty early career fellowship from NHMRC, Australia. VP additionally received Ph.D. scholarship support in Melbourne from Becas Chile and the University of Talca where he now holds a faculty position. |